PLX - from their 10K filed today:
"In February 2010, the Israeli MOH completed a successful good manufacturing practices (GMP) audit of our manufacturing facilities in
Carmiel, Israel. The audit was performed as part of the Israeli MOH's evaluation of our manufacturing process for taliglucerase alfa. On
February 20, 2011, we received a letter from the FDA notifying us that the FDA had completed its review of the Establishment Inspection Report in
connection with the FDA's inspection of our facility in Carmiel, Israel, and that the FDA had classified our facility as acceptable."
I think this is very positive for PLX.
